Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159287 | 0.94 | TLR4 (0.35) | HPGDCYP2C9 | |
| SCHEMBL8735525 | 0.94 | CYP1A2 (0.36) | HPGDCYP2C9LMNAMAPTCYP1A2 | |
| SCHEMBL8013943 | 0.89 | HPGD (0.35) | HPGD | |
| SCHEMBL1893345 | 0.88 | CYP1A2 (0.47) | HPGDCYP2C9LMNAMAPTCYP1A2 | |
| SCHEMBL504003 | 0.86 | CYP1A2 (0.41) | HPGDCYP2C9LMNAMAPTCYP1A2 | |
| SCHEMBL1896640 | 0.85 | HTT (0.40) | CYP2C9ALDH1A1LMNAMAPTCYP1A2 | |
| SCHEMBL8975284 | 0.85 | HTT (0.40) | CYP2C9ALDH1A1LMNAMAPTCYP1A2 | |
| SCHEMBL5862504 | 0.85 | HTT (0.40) | CYP2C9ALDH1A1LMNAMAPTCYP1A2 | |
| SCHEMBL11290481 | 0.85 | HTT (0.40) | CYP2C9ALDH1A1LMNAMAPTCYP1A2 | |
| SCHEMBL4170126 | 0.83 | CYP1A2 (0.42) | HPGDCYP2C9LMNAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4348298-A | WITH DICHROIC DYESTUFF | VEB WERK FUR FERNSEHELEKTRONIK IM VEB KOMBINAT MIKROELEKTRONIK (DD) | 1982-09-07 | — | — | US | claimed |
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| WO-2015173168-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0688752-B1 | Trifluoro-2-(trans-4-substituted cyclohexyl) ethylenes and process for their production | ASAHI GLASS CO LTD (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5621147-A | LIQUID CRYSTAL INTERMEDIATES | ASAHI GLASS COMPANY LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0688752-A1 | Trifluoro-2-(trans-4-substituted cyclohexyl) ethylenes and process for their production | ASAHI GLASS COMPANY LTD. (JP) | 1995-12-27 | — | — | EP | disclosed |
| EP-0413785-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS. | MERCK PATENT GMBH (DE) | 1991-02-27 | — | — | EP | disclosed |
| WO-1990009420-A1 | LIQUID CRYSTALLINE MEDIA CONTAINING FLUORINATED OLIGOPHENYLS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-08-23 | — | — | WO | disclosed |
| US-4361494-A | Anisotropic cyclohexyl cyclohexylmethyl ethers | BBC BROWN, BOVERI, & COMPANY, LIMITED (CH) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | HPGD 4399/4885CYP2C9 3509/4885ALDH1A1 2470/4885 |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | HPGD 772/4885CYP2C9 1191/4885ALDH1A1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.